Cases of primary multiple malignant tumors, with one localized in the stomach, have been studied. In cases of radical surgery, second tumors were detected in 6.2% while in patients with early gastric cancer--twice as many (12.5%). Among second tumors, most frequent were neoplasms of large bowel, urogenital system, head and neck, lung, skin and breast. Radical surgery for gastric cancer was carried out in 94%, palliative resection--6%. Radical surgery for second tumors was performed in 53 (82%), palliative--7 (11%). Surgery for second tumors was used in 38%, combined treatment--27%. Synchronous and, in particular, metachronous tumors were mostly responsible for deaths among those radically treated for stomach cancer. In general, second tumors failed to significantly impact the end results of that pathology (p=0.13). Hence, primary multiple tumors should not be regarded as counterindications for radical treatment, a combined one included, of the either neoplasm, nor does it contribute to postoperative lethality rates. Prior to surgery and during clinical course, it is important to make sure that there are no synchronous or metachronous tumors in sites where they generally occur.

Download full-text PDF

Source

Publication Analysis

Top Keywords

second tumors
20
primary multiple
12
radical surgery
12
surgery second
12
tumors
10
multiple malignant
8
malignant tumors
8
synchronous metachronous
8
metachronous tumors
8
surgery
5

Similar Publications

Background: Kidney tumors, common in the urinary system, have widely varying survival rates post-surgery. Current prognostic methods rely on invasive biopsies, highlighting the need for non-invasive, accurate prediction models to assist in clinical decision-making.

Purpose: This study aimed to construct a K-means clustering algorithm enhanced by Transformer-based feature transformation to predict the overall survival rate of patients after kidney tumor resection and provide an interpretability analysis of the model to assist in clinical decision-making.

View Article and Find Full Text PDF

Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy.

Apoptosis

January 2025

Department of Breast Cancer Surgery, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, No. 519 Beijing East Road, Nanchang, Jiangxi, 330029, China.

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide. Immunotherapy, a promising therapeutic approach, often faces challenges due to the immunosuppressive tumor microenvironment. This study explores the innovative use of CRISPR-Cas9 technology in conjunction with FCPCV nanoparticles to target and edit the C-C Motif Chemokine Ligand 5 (CCL5) gene, aiming to improve the efficacy of breast cancer immunotherapy.

View Article and Find Full Text PDF

Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.

Nat Chem Biol

January 2025

Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.

RAF protein kinases are major RAS effectors that function by phosphorylating MEK. Although all three RAF isoforms share a conserved RAS binding domain and bind to GTP-loaded RAS, only ARAF uniquely enhances RAS activity. Here we uncovered the molecular basis of ARAF in regulating RAS activation.

View Article and Find Full Text PDF

The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified.

View Article and Find Full Text PDF

Absent in melanoma 2: a potent suppressor of retinal pigment epithelial-mesenchymal transition and experimental proliferative vitreoretinopathy.

Cell Death Dis

January 2025

Laboratory of Developmental Cell Biology and Disease, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.

Epithelial-to-mesenchymal transition (EMT) is a critical and complex process involved in normal embryonic development, tissue regeneration, and tumor progression. It also contributes to retinal diseases, such as age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR). Although absent in melanoma 2 (AIM2) has been linked to inflammatory disorders, autoimmune diseases, and cancers, its role in the EMT of the retinal pigment epithelium (RPE-EMT) and retinal diseases remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!